Q&A With Marc Ditmarsch From AstraZeneca: Continued Research of Ticagrelor Shows Benefits of Earlier Use
Patients in the emergency room for a recent heart attack may be prescribed ticagrelor by the attending physician. A recent study showed getting patients the treatment as early as in the ambulance can provide additional benefits.
Patients in the emergency room for a recent heart attack may be prescribed ticagrelor by the attending physician. A recent study showed getting patients the treatment as early as in the ambulance can provide additional benefits.
Marc Ditmarsch, MD, Global Product Vice Preident CV/GI Global Medicines Development, from AstraZeneca addressed addtional testing on the treatment which is also known by the brand name of Brilinta during the European Society of Cardiology's annual congress in London.
As a tablet taken orally ticagrelor can be easily administered but there are certain risks that need to be considered when prescribing the therapy. There is also more work being done to determine who should and should not use the drug.
For as much as doctors prescribe medications they are only as good as likelihood of patients taking them as they are supposed to. In the age of smart phones a simple text message can go a long way in helping patients stay on track.
